β€’
Nov 30, 2020

AngioDynamics Q2 2021 Earnings Report

Reported a revenue increase driven by sales execution and expense management, resulting in positive earnings.

Key Takeaways

AngioDynamics reported a 4.0% increase in net sales to $72.8 million compared to the prior-year quarter. The company's gross margin declined to 55.2%, and GAAP loss per share was $0.11, while adjusted earnings per share was $0.01. They reaffirmed their fiscal year 2021 net sales guidance between $278 and $284 million and adjusted earnings per share between $0.00 and $0.05.

Net sales increased 4.0% compared to the prior-year quarter, reaching $72.8 million.

Gross margin declined 410 basis points year over year to 55.2%.

GAAP loss per share was $0.11, while adjusted earnings per share was $0.01.

Cash and cash equivalents were $58.0 million, compared to $47.9 million on August 31, 2020.

Total Revenue
$72.8M
Previous year: $70M
+4.0%
EPS
$0.01
Previous year: $0.06
-83.3%
Gross Margin
55.2%
Previous year: 59.3%
-6.9%
Gross Profit
$40.2M
Previous year: $41.5M
-3.3%
Cash and Equivalents
$58M
Previous year: $41.2M
+40.6%
Free Cash Flow
$10.1M
Previous year: $3.31M
+204.4%
Total Assets
$589M
Previous year: $725M
-18.8%

AngioDynamics

AngioDynamics

AngioDynamics Revenue by Geographic Location

Forward Guidance

The Company continues to expect fiscal year 2021 net sales in the range of $278 to $284 million and fiscal year 2021 adjusted earnings per share in the range of $0.00 to $0.05.

Revenue & Expenses

Visualization of income flow from segment revenue to net income